Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Phase 2 TRITON trial of Descartes-08 in ...
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement ...
Zacks.com on MSN
Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?
Cartesian Therapeutics, Inc. (RNAC) shares ended the last trading session 10.3% higher at $7.04. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...
Cartesian Therapeutics' lead asset, Descartes-08, demonstrated a 7.1-point MG-ADL reduction at 12 months in Phase 2b. Find ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases, eliminating the need for preconditioning chemotherapy. Lead candidate Descartes-08 showed promising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results